KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. Co. has develop small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). Co. also is conducting preclinical development on an oral Factor XIIa inhibitor program, which Co. is initially improving to provide HAE therapeutics. Co. has developed its candidate sebetralstat into clinical development as a potential oral, on-demand therapy for HAE attacks. Co. also is developing an oral disintegrating tablet formulation of sebetralstat. We show 28 historical shares outstanding datapoints in our KALV shares outstanding history coverage, used to compute KALV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KALV market cap history over the course of time is important for investors
interested in comparing KALV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KALV versus a peer is one thing; comparing
KALV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KALV can fluctuate over the course of history.
With this page we aim to empower investors researching KALV by allowing them to research the KALV market cap history. |
Free KALV Email Alerts:
Video: The Importance of Market Cap
